Company news
Immutep Ltd news in 2026
Immutep Ltd's news releases, calls and decks from 2026, newest first.
Immutep Quarterly Activities Report and Appendix 4C
October 28, 2026
Immutep Receives A$2.16 million French R&D Tax Incentive
October 27, 2026
Notice of Annual General Meeting/Proxy Form
October 26, 2026
Appendix 4G and Corporate Governance Statement
October 26, 2026
Annual Report to shareholders
October 26, 2026
Annual Report filed on Form 20-F
October 25, 2026
Quality of Life Data from EFTISARC-NEO presented at ESMO
October 23, 2026
Late-Breaking Abstract on IMP761 to be presented at ACR 2026
October 18, 2026
2026 Annual General Meeting and Key Dates
October 14, 2026
Immutep & Monash Secure Further ARC Funding for LAG-3
October 13, 2026
Immutep Regains Compliance with Nasdaq
October 12, 2026
Audit and Risk Committee Update
October 9, 2026
Final Director's Interest Notice - P Meyers
October 4, 2026
Notification of cessation of securities - IMM
October 4, 2026
Resignation of Non-Executive Director
October 4, 2026
Change of Director's Interest Notice - P Meyers
September 30, 2026
Application for quotation of securities - IMM
September 30, 2026
Immutep Receives ~A$0.86 Million R&D Tax Incentive
September 29, 2026
Immutep receives Australian R&D Tax Incentive
September 29, 2026
Change to American Depositary Share Ratio
September 21, 2026
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
September 11, 2026
Immutep Outlines Focused Development Strategy for Efti
September 10, 2026
S&P DJI Announces September 2026 Quarterly Rebalance
September 4, 2026
Appendix 4E & 2026 Full Year Statutory Accounts
August 30, 2026
Immutep Corporate Presentation
August 19, 2026
Immutep Quarterly Activities Report Q4 FY26
July 30, 2026
Immutep Quarterly Activities Report and Appendix 4C
July 29, 2026
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
July 23, 2026
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
July 14, 2026
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
July 12, 2026
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
May 27, 2026
Immutep Receives Nasdaq Notice of Bid Price Deficiency
April 30, 2026
Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
April 22, 2026
Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
April 15, 2026
Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma
April 14, 2026
Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
March 19, 2026
Update on Phase I Study of IMP761 for Autoimmune Diseases
March 18, 2026
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
March 13, 2026
TACTI-004 to be discontinued following futility analysis
March 12, 2026
Reinstatement to Quotation
March 12, 2026
Suspension from Quotation
March 10, 2026
Trading Halt
March 6, 2026
Half Yearly Report and Accounts
February 24, 2026
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
February 6, 2026
Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC
February 5, 2026
Immutep Quarterly Activities Report Q2 FY26
January 29, 2026
Immutep Quarterly Activities Report and Appendix 4C
January 29, 2026
Decks in 2026
- Investor Presentation (August 2026)
Investor deck · 30 slides · Aug 20, 2026
- Investor Presentation (February 2026)
Investor deck · 39 slides · Feb 20, 2026